• Corpus ID: 74479699

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

@article{Turner1998IntensiveBC,
  title={Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.},
  author={Robert C. Turner and C Fox and Matthews and Helen Mcelroy and Carole A. Cull and Rury R. Holman and Patel Neil and D. R. Hadden and David W. Wright and {\'E}abha Manley and Irene M. Stratton and Uk Prospective Diabetes and Eva M. Kohner and Frighi and Michael Gnant},
  journal={The Lancet},
  year={1998}
}
Background Improved blood-glucose control decreases the progression of diabetic microvascular disease, but the effect on macrovascular complications is unknown. There is concern that sulphonylureas may increase cardiovascular mortality in patients with type 2 diabetes and that high insulin concentrations may enhance atheroma formation. We compared the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and… 
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
TLDR
The proportion of patients who maintained target glycemic levels declined markedly over 9 years of follow-up, and the progressive deterioration of diabetes control was such that after 3 years approximately 50% of patients could attain this goal with monotherapy, and by 9 years this declined to approximately 25%.
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
TLDR
The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions, and each of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources.
Combination therapies with insulin in type 2 diabetes.
TLDR
These data demonstrated that neither insulin nor sulfonylureas, despite causing hyperinsulinemia and weight gain, have adverse effects on cardiovascular outcome, and it is now known that 14 U of long-acting insulin is insufficient to control fasting glycemia in most type 2 diabetic patients.
Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study.
TLDR
Many people with type 2 diabetes received inadequate monitoring and had poor glycaemic control, and intensive management is required to reduce the risk of microvascular complications.
Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial
TLDR
Intensive glucose control was not associated with a significant reduction in macrovascular events; however, unlike reports from the recently reported Action to Control Cardiovascular Risk in Diabetes (ACCORD), there was no evidence of any increase in all-cause mortality or cardiovascular death with more intensive glucose control.
Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes
TLDR
The effects of routine blood pressure lowering and intensive glucose control were independent of one another, and when combined, they produced additional reductions in clinically relevant outcomes.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
TLDR
Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to Diabetes, progression of diabetic retinopathy, and deterioration in visual acuity.
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus
TLDR
Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM.
U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease
TLDR
Sulfonylurea, metformin, and insulin therapies were similarly effective in improving glucose control compared with a policy of diet therapy and whether any specific therapy is advantageous or disadvantageous.
Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial
TLDR
Intensive CIT, when combined with CBG measurements, can be used to rapidly improve glycemic control in type II diabetes without development of unacceptable hypoglycemia, however, this degree of metabolic improvement requires large doses of exogenous insulin to overcome peripheral insulin resistance and results in greater hyperinsulinemia with progressive weight gain.
UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes
TLDR
Early addition of metformin improved gly glucose control in patients with suboptimal glycemic control while taking maximum sulfonylurea therapy, irrespective of obesity or baseline FPG concentrations.
United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus
TLDR
The prospective data in patients with NIDDM suggest that hyperglycemia is a risk factor for cardiovascular disease, but insufficient data exist to determine whether there is a glycemic threshold for macrovascular disease.
Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trial
TLDR
Intense stepped insulin therapy in NIDDM patients who have failed glycemic control on pharmacological therapy is effective in maintaining near-normal gly glucose control for > 2 years without excessive severe hypoglycemia, weight gain, hypertension, or dyslipidemia.
Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
TLDR
The study design allowed us to evaluate the effects of metformin vs. placebo treatment on glycemic control, plasma lipid profile, HGP, insulin-mediated glucose uptake, oxidative and nonoxidative glucose metabolism, and lactate turnover and there were no changes in any of the above metabolic parameters in the placebo-treated group.
Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups
TLDR
It is indicated that metformin treatment improves glycemic control, and lowers insulin resistance and risk factors for cardiovascular disease, including PAI-1, and may therefore be useful in the long-term management of NIDDM subjects who have a high risk of cardiovascular disease.
...
...